Resumen de Identificació de metabòlits com biomarcadors i mediadors de inflamació en artritis inflamatòries
Inflammatory arthritis represents a great social and economic burden despite recent therapeutic advances. Although we have a better understanding of the pathogenic mechanisms, treatment election is still made on a trial basis, which leads to lack of control of disease activity in approximately 30% of patients and a high rate of side effects. The identification of disease mediators and predictors of response to treatment are needed to allow the adequate treatment and achieve clinical remission or at least low disease activity. A single biomarker is unlikely to provide sufficient information to explain these heterogeneous diseases. Metabolomics is a tool that can be used for biomarker discovery as it can identify profiles of a large number of metabolites in different types of samples. Metabolites are not just the end result of chemical processes that occur in the cell, but also play critical role in a variety of cellular processes, such as post-translational modifications and immune cell regulation. With the hypothesis that circulating metabolites reflect synovial processes, this project aimed to study circulating metabolites in relation to disease activity and response to disease modifying anti- rheumatic drugs. We described different metabolomic profiles in patients with inflammatory arthritis compared to controls. We also identified metabolites that correlate with disease activity and that may be mediators of disease, as well as metabolites that are associated with response to treatment.
